Investigational drug · Phase 3
OCS-01
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Macular Edema.
Phase 3Last checked: Nov 19, 2026Latest source record: May 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
6
Any phase or sponsor naming "OCS-01"
First trial start
2021
Oct 19, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OCS-01", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Macular Edema
Approved drugs for the same conditions: Diabetic macular edema · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "OCS-01" as an intervention, largest first.
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)Pivotal-lookingCompleted
OculisIndustry
NCT05066997 · 552 participants · Start Oct 19, 2021 · Primary completion Apr 10, 2026
Drug: Dexamethasone ophthalmic suspension (OCS-01); Vehicle · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Springdale, Arkansas; Beverly Hills, California · 52 sites in all
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2)Pivotal-lookingCompleted
OculisIndustry
NCT06172257 · 401 participants · Start Mar 15, 2024 · Primary completion Apr 2, 2026
Drug: Dexamethasone ophthalmic suspension (OCS-01); Vehicle · For: Diabetic Macular Edema
Sites: Gilbert, Arizona; Phoenix, Arizona; Bakersfield, California · 62 sites in all
- A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryPivotal-lookingCompleted
OculisIndustry
NCT05147233 · 241 participants · Start Jun 24, 2022 · Primary completion Jun 22, 2023
Drug: OCS-01; Vehicle · For: Inflammation Eye Pain; Postoperative Cataract
Sites: Chandler, Arizona; Phoenix, Arizona; Fayetteville, Arkansas · 25 sites in all
- OCS-01 in Treating Inflammation and Pain in Post-cataract PatientsPivotal-lookingCompleted
OculisIndustry
NCT04130802 · 153 participants · Start Sep 27, 2019 · Primary completion Jan 31, 2020
Drug: OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL; Placebo · For: Inflammation Corneal; Pain, Postoperative
Sites: Petaluma, California; Roseburg, Oregon; Houston, Texas · 4 sites in all
- A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract SurgeryPivotal-lookingTerminated
OculisIndustry
NCT06128369 · 117 participants · Start Dec 18, 2023 · Primary completion May 2, 2024
Drug: OCS-01; Vehicle · For: Inflammation Eye Pain; Postoperative Cataract
Sites: Glendale, California; Inglewood, California; Newport Beach, California · 24 sites in all
- Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular EdemaActive, not recruiting
Quan Dong NguyenAcademic, hospital or other
NCT05608837 · 28 participants · Start May 26, 2023 · Primary completion Oct 2026
Drug: OCS-01 · For: Uveitis Related Cystoid Macular Edema; Cystoid Macular Edema, Postoperative
Sites: Beverly Hills, California; Huntington Beach, California; Los Angeles, California · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Safety and efficacy of topical OCS-01 ophthalmic suspension for the treatment of diabetic macular oedema: stage 1 of a multicentre, double-blind, randomised, vehicle-controlled phase 2/3 trial.
Khanani AM, Tadayoni R, Markabi S, et al. · EClinicalMedicine 2026
- Beyond the injection: delivery systems reshaping retinal disease management.
Rowe LW, Akotoye C, Harris A, et al. · Expert Opin Pharmacother 2025
- Topical treatment of diabetic macular edema using dexamethasone ophthalmic suspension: A randomized, double-masked, vehicle-controlled study.
Stefansson E, Loftsson T, Larsen M, et al. · Acta Ophthalmol 2023
- OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study.
Korenfeld M, Gira J, Jong K, et al. · Clin Ther 2022
Also in development for Diabetic Macular Edema
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- AVT29proposed aflibercept HD biosimilarPhase 31 trial
Alvotech Swiss AG · Diabetic Macular Edema
- Intravitreal RanibizumabPhase 31 trial
Roche (Genentech) · Diabetic Macular Edema
- BI 3812465Phase 21 trial
Boehringer Ingelheim · Diabetic Macular Edema
- CU06-1004Phase 21 trial
Curacle Co., Ltd. · DME, Diabetic Macular Edema, Diabetic Macular Edema (DME)
- OXU-001DEXAspheresPhase 21 trial
Oxular Limited · Diabetic Macular Edema
- RO7446603Phase 21 trial
Roche (Genentech) · Diabetic Macular Edema
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.